Animal models of yellow fever and their application in clinical research

Current Opinion in Virology

Volumn 18, Issue , 2016, Pages 64-69

  Julander, Justin G ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ANIMAL MODEL; CLINICAL RESEARCH; HAMSTER MODEL; HUMAN; INFORMATION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; MOUSE MODEL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; SOUTH AMERICA; YELLOW FEVER; YELLOW FEVER VIRUS; ANIMAL; DISEASE MODEL; HAMSTER; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; RHESUS MONKEY; VIROLOGY;

ANIMALS; BIOMEDICAL RESEARCH; CRICETINAE; DISEASE MODELS, ANIMAL; MACACA MULATTA; MICE; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 84963811848     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.03.010     Document Type: Review

References (37)

1. B.R. Ellis, and A.D. Barrett The enigma of yellow fever in East Africa Rev Med Virol 18 2008 331 346
2. T.P. Monath, and P.F. Vasconcelos Yellow fever J Clin Virol 64 2015 160 173
3. E.S. Moreno, R. Spinola, C.H. Tengan, R.A. Brasil, M.M. Siciliano, T.L. Coimbra, V.R. Silveira, I.M. Rocco, I. Bisordi, R.P. Souza, S. Petrella, and et al. Yellow fever epizootics in non-human primates, Sao Paulo state, Brazil, 2008-2009 Rev Inst Med Trop Sao Paulo 55 2013 45 50
4. M.A. de Almeida, E. Dos Santos, J. da Cruz Cardoso, D.F. da Fonseca, C.A. Noll, V.R. Silveira, A.Y. Maeda, R.P. de Souza, C. Kanamura, and R.A. Brasil Yellow fever outbreak affecting alouatta populations in southern Brazil (Rio Grande do Sul state), 2008-2009 Am J Primatol 74 2012 68 76
5. T.P. Monath, S.J. Seligman, J.S. Robertson, B. Guy, E.B. Hayes, R.C. Condit, J.L. Excler, L.M. Mac, B. Carbery, R.T. Chen Brighton Collaboration Viral Vector Vaccines Safety Working Group Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment Vaccine 33 2015 62 72
6. K.A. Hanley, T.P. Monath, S.C. Weaver, S.L. Rossi, R.L. Richman, and N. Vasilakis Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus Infect Genet Evol 19 2013 292 311
7. J.G. Julander Experimental therapies for yellow fever Antiviral Res 97 2012 169 179
8. A.A. Perelygin, S.V. Scherbik, I.B. Zhulin, B.M. Stockman, Y. Li, and M.A. Brinton Positional cloning of the murine flavivirus resistance gene Proc Natl Acad Sci U S A 99 2002 9322 9327
9. M. Laurent-Rolle, J. Morrison, R. Rajsbaum, J.M. Macleod, G. Pisanelli, A. Pham, J. Ayllon, L. Miorin, C. Martinez-Romero, B.R. tenOever, and A. Garcia-Sastre The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon Cell Host Microbe 16 2014 314 327
10. M. Maciel Jr., S. Cruz Fda, M.T. Cordeiro, M.A. da Motta, K.M. Cassemiro, C. Maia Rde, R.C. de Figueiredo, R. Galler, S. Freire Mda, J.T. August, E.T. Marques, and et al. A DNA vaccine against yellow fever virus: development and evaluation PLoS Negl Trop Dis 9 2015 e0003693
11. B. Schafer, G.W. Holzer, A. Joachimsthaler, S. Coulibaly, M. Schwendinger, B.A. Crowe, T.R. Kreil, P.N. Barrett, and F.G. Falkner Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever PLoS ONE 6 2011 e24505
12. S. Sukupolvi-Petty, S.K. Austin, M. Engle, J.D. Brien, K.A. Dowd, K.L. Williams, S. Johnson, R. Rico-Hesse, E. Harris, T.C. Pierson, D.H. Fremont, and et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2 J Virol 84 2010 9227 9239
13. J.C. Moulin, J. Silvano, V. Barban, P. Riou, and C. Allain Yellow fever vaccine: comparison of the neurovirulence of new 17D-204 stamaril seed lots and RK 168-73 strain Biologicals 41 2013 238 246
14. K.C. Meier, C.L. Gardner, M.V. Khoretonenko, W.B. Klimstra, and K.D. Ryman A mouse model for studying viscerotropic disease caused by yellow fever virus infection PLoS Pathog 5 2009 e1000614
15. A.K. Erickson, and J.K. Pfeiffer Spectrum of disease outcomes in mice infected with yfv-17d J Gen Virol 96 Pt 6 2015 1328 1339
16. I. Tretyakova, B. Nickols, R. Hidajat, J. Jokinen, I.S. Lukashevich, and P. Pushko Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice Virology 468-470 2014 28 35
17. A.K. Erickson, and J.K. Pfeiffer Dynamic viral dissemination in mice infected with yellow fever virus strain 17D J Virol 87 2013 12392 12397
18. B.A. Thibodeaux, N.C. Garbino, N.M. Liss, J. Piper, C.D. Blair, and J.T. Roehrig A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain Vaccine 30 2012 3180 3187
19. B.A. Thibodeaux, N.C. Garbino, N.M. Liss, J. Piper, J.J. Schlesinger, C.D. Blair, and J.T. Roehrig A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model Antiviral Res 94 2012 1 8
20. J.G. Julander, B.A. Thibodeaux, J.D. Morrey, J.T. Roehrig, and C.D. Blair Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model Antiviral Res 103 2014 32 38
21. J.D. Albarnaz, L.C. De Oliveira, A.A. Torres, R.M. Palhares, M.C. Casteluber, C.M. Rodrigues, P.L. Cardozo, A.M. De Souza, C.C. Pacca, P.C. Ferreira, E.G. Kroon, and et al. MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target Antiviral Res 111 2014 82 92
22. T.P. Monath Treatment of yellow fever Antiviral Res 78 2008 116 124
23. J.G. Julander, S. Bantia, B.R. Taubenheim, D.M. Minning, P. Kotian, J.D. Morrey, D.F. Smee, W.P. Sheridan, and Y.S. Babu BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model Antimicrob Agents Chemother 58 2014 6607 6614
24. J.G. Julander, K. Shafer, D.F. Smee, J.D. Morrey, and Y. Furuta Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 Antimicrob Agents Chemother 53 2009 202 209
25. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antiviral Res 100 2013 446 454
26. T.K. Warren, J. Wells, R.G. Panchal, K.S. Stuthman, N.L. Garza, S.A. Van Tongeren, L. Dong, C.J. Retterer, B.P. Eaton, G. Pegoraro, S. Honnold, and et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 Nature 508 2014 402 405
27. Z. Fan, W. Li, S.R. Lee, Q. Meng, B. Shi, T.D. Bunch, K.L. White, I.K. Kong, and Z. Wang Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system PLOS ONE 9 2014 e109755
28. K. Toth, S.R. Lee, B. Ying, J.F. Spencer, A.E. Tollefson, J.E. Sagartz, I.K. Kong, Z. Wang, and W.S. Wold Stat2 knockout Syrian hamsters support enhanced replication and pathogenicity of human adenovirus, revealing an important role of type I interferon response in viral control PLoS Pathog 11 2015 e1005084
29. T.P. Monath, and A.D. Barrett Pathogenesis and pathophysiology of yellow fever Adv Virus Res 60 2003 343 395
30. G. Li, T. Duan, X. Wu, R.B. Tesh, L. Soong, and S.Y. Xiao Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes Int J Clin Exp Pathol 1 2008 169 179
31. D.W. Beasley, A.J. McAuley, and D.A. Bente Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy Antiviral Res 115 2015 48 70
32. J.N. Mandl, R. Akondy, B. Lawson, N. Kozyr, S.I. Staprans, R. Ahmed, and M.B. Feinberg Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host J Immunol 186 2011 6406 6416
33. F. Engelmann, L. Josset, T. Girke, B. Park, A. Barron, J. Dewane, E. Hammarlund, A. Lewis, M.K. Axthelm, M.K. Slifka, and I. Messaoudi Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model PLoS Negl Trop Dis 8 2014 e3295
34. J.G. Julander, D.W. Trent, and T.P. Monath Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model Vaccine 29 2011 6008 6016
35. T.P. Monath, C.K. Lee, J.G. Julander, A. Brown, D.W. Beasley, D.M. Watts, E. Hayman, P. Guertin, J. Makowiecki, J. Crowell, P. Levesque, and et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity Vaccine 28 2010 3827 3840
36. P.D. Minor Neurovirulence tests of three 17D yellow fever vaccine strains Biologicals 39 2011 167 170
37. P.C. Neves, R.A. Rudersdorf, R. Galler, M.C. Bonaldo, M.G. de Santana, P.A. Mudd, M.A. Martins, E.G. Rakasz, N.A. Wilson, and D.I. Watkins CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses Vaccine 28 2010 8183 8188